The modified Glasgow Prognostic Score (mGPS), a composite biomarker using albumin and C reactive protein (CRP), has been shown to be a good predictor of outcomes in ccRCC patients treated with immunotherapy. This evidence concerns the gene CRP and nonpapillary renal cell carcinoma.